CustomEX™ Platform

About ReNeuron

ReNeuron is a public biotechnology company transitioning from a pioneer in clinical-stage regenerative medicine to a focused exosome platform developer. Its core asset is the CustomEX™ platform, which utilizes a library of proprietary, conditionally immortalized stem cell lines to produce exosomes with innate tissue-targeting capabilities for drug delivery. The strategy is to advance internal pipeline candidates and establish strategic partnerships, building on a legacy that includes the world's first clinical trial of a neural stem cell therapy for stroke.

Therapeutic Areas